Short answer
FATE THERAPEUTICS INC (FATE) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
FATE THERAPEUTICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Exhibit 99.1 contains Fate Therapeutics’ detailed financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $2.1M; net loss $30.2M, or $(0.25) per share, versus $(0.29) in Q2 2025
- Cash, equivalents, and investments $153.8M after a $21M quarterly decrease; operating runway expected into 2028
- FT819 entered Phase 2 potentially registrational RECLAIM-LN trial; enrollment target approximately 53 patients by first half 2028
- FT819’s first lupus nephritis patient received outpatient treatment with same-day discharge, supporting off-the-shelf access and scalability
- FDA cleared FT839 IND for Phase 1/2 autoimmune basket trial, expanding Fate’s dual CD19/CD38 product pipeline beyond FT819
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FATE THERAPEUTICS INC 8-K filings
Get the next FATE 8-K as it lands
Follow FATE for push alerts, or ask the research agent what this filing means.